Literature DB >> 19027286

Neurotropin reverses paclitaxel-induced neuropathy without affecting anti-tumour efficacy.

Takehiro Kawashiri1, Nobuaki Egashira, Yoshinori Itoh, Takao Shimazoe, Yoko Ikegami, Takahisa Yano, Megumu Yoshimura, Ryozo Oishi.   

Abstract

Paclitaxel is a commonly used anticancer drug, but it frequently causes peripheral neuropathy. Neurotropin, a non-protein extract from inflamed rabbit skin inoculated with vaccinia virus, has been used to treat various chronic painful conditions. In the present study, we investigated the effect of neurotropin on the paclitaxel-induced neuropathy in rats. Repeated administration of paclitaxel induced mechanical allodynia, cold hyperalgesia, and motor dysfunction. These neuropathies were mostly reversed by the repeated administration of neurotropin. Furthermore, neurotropin ameliorated the paclitaxel-induced axonal degeneration in cultured PC12 and rat dorsal root ganglion cells, and in rat sciatic nerve. In addition, neurotropin did not affect the microtubule aggregation or anti-tumour effect induced by paclitaxel in the tumour cell lines or tumour cells-implanted mice. These results suggest that neurotropin reverses the paclitaxel-induced neuropathy without affecting anti-tumour activity of paclitaxel, and therefore may be useful for the paclitaxel-induced neuropathy in clinical settings.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19027286     DOI: 10.1016/j.ejca.2008.10.004

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  10 in total

1.  Prolonged regulatable expression of EPO from an HSV vector using the LAP2 promoter element.

Authors:  Z Wu; M Mata; D J Fink
Journal:  Gene Ther       Date:  2011-11-17       Impact factor: 5.250

Review 2.  Animal models of chemotherapy-evoked painful peripheral neuropathies.

Authors:  Nicolas Authier; David Balayssac; Fabien Marchand; Bing Ling; Aude Zangarelli; Juliette Descoeur; François Coudore; Emmanuel Bourinet; Alain Eschalier
Journal:  Neurotherapeutics       Date:  2009-10       Impact factor: 7.620

3.  Neuroprotective effect of neurotropin on chronic oxaliplatin-induced neurotoxicity in stage II and stage III colorectal cancer patients: results from a prospective, randomised, single-centre, pilot clinical trial.

Authors:  R X Zhang; Z H Lu; D S Wan; X J Wu; P R Ding; L H Kong; Z Z Pan; G Chen
Journal:  Int J Colorectal Dis       Date:  2012-06-05       Impact factor: 2.796

4.  Evaluation of lercanidipine in Paclitaxel-induced neuropathic pain model in rat: a preliminary study.

Authors:  Lekha Saha; Debasish Hota; Amitava Chakrabarti
Journal:  Pain Res Treat       Date:  2012-03-25

5.  Neurotropin suppresses inflammatory cytokine expression and cell death through suppression of NF-κB and JNK in hepatocytes.

Authors:  Bi Zhang; Yoon Seok Roh; Shuang Liang; Cheng Liu; Mitsuru Naiki; Koichi Masuda; Ekihiro Seki
Journal:  PLoS One       Date:  2014-12-03       Impact factor: 3.240

6.  Kamishoyosan and Shakuyakukanzoto promote recovery from paclitaxel-induced neurite retraction in PC12 cells.

Authors:  Ken Konaka; Kota Moriyama; Takumi Sakurada; Naoto Okada; Masaki Imanishi; Yoshito Zamami; Kazuyoshi Kawazoe; Shuji Fushitani; Keisuke Ishizawa
Journal:  J Pharm Health Care Sci       Date:  2017-07-21

7.  Regulatable Transgene Expression for Prevention of Chemotherapy-Induced Peripheral Neuropathy.

Authors:  Daisuke Kawata; Zetang Wu
Journal:  Mol Ther Methods Clin Dev       Date:  2017-06-21       Impact factor: 6.698

8.  Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a VAC14 Polymorphism that Increases Risk of Docetaxel-Induced Neuropathy.

Authors:  Daniel L Hertz; Kouros Owzar; Sherrie Lessans; Claudia Wing; Chen Jiang; William Kevin Kelly; Jai Patel; Susan Halabi; Yoichi Furukawa; Heather E Wheeler; Alexander B Sibley; Cameron Lassiter; Lois Weisman; Dorothy Watson; Stefanie D Krens; Flora Mulkey; Cynthia L Renn; Eric J Small; Phillip G Febbo; Ivo Shterev; Deanna L Kroetz; Paula N Friedman; John F Mahoney; Michael A Carducci; Michael J Kelley; Yusuke Nakamura; Michiaki Kubo; Susan G Dorsey; M Eileen Dolan; Michael J Morris; Mark J Ratain; Howard L McLeod
Journal:  Clin Cancer Res       Date:  2016-05-03       Impact factor: 12.531

9.  Neurotropin® Accelerates the Differentiation of Schwann Cells and Remyelination in a Rat Lysophosphatidylcholine-Induced Demyelination Model.

Authors:  Hozo Matsuoka; Hiroyuki Tanaka; Junichi Sayanagi; Toru Iwahashi; Koji Suzuki; Shunsuke Nishimoto; Kiyoshi Okada; Tsuyoshi Murase; Hideki Yoshikawa
Journal:  Int J Mol Sci       Date:  2018-02-08       Impact factor: 5.923

10.  Neuroprotection by Neurotropin through Crosstalk of Neurotrophic and Innate Immune Receptors in PC12 Cells.

Authors:  Yu Fukuda; Kazuki Nakajima; Tatsuro Mutoh
Journal:  Int J Mol Sci       Date:  2020-09-04       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.